Meitav Investment House’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $126M | Sell |
794,579
-15,000
| -2% | -$2.03M | 0.85% | 31 |
|
|
2026
Q1 | $103M | Sell |
809,579
-159,840
| -16% | -$20M | 1.13% | 23 |
|
|
2025
Q4 | $118M | Buy |
969,419
+287,363
| +42% | +$32.9M | 1.36% | 20 |
|
|
2025
Q3 | $68.2M | Buy |
682,056
+281,602
| +70% | +$25.4M | 0.9% | 28 |
|
|
2025
Q2 | $33.2M | Buy |
400,454
+383,040
| +2,200% | +$30.6M | 0.45% | 51 |
|
|
2025
Q1 | $1.41M | Hold |
17,414
| – | – | 0.03% | 122 |
|
|
2024
Q4 | $1.57M | Sell |
17,414
-47,370
| -73% | -$4.59M | 0.03% | 117 |
|
|
2024
Q3 | $6.4M | Sell |
64,784
-1,810
| -3% | -$178K | 0.11% | 84 |
|
|
2024
Q2 | $6.17M | Hold |
66,594
| – | – | 0.11% | 87 |
|
|
2024
Q1 | $6.32M | Sell |
66,594
-237,210
| -78% | -$22M | 0.12% | 83 |
|
|
2023
Q4 | $27.1M | Sell |
303,804
-70,575
| -19% | -$5.24M | 0.4% | 71 |
|
|
2023
Q3 | $27.7M | Sell |
374,379
-3,499
| -0.9% | -$279K | 0.45% | 63 |
|
|
2023
Q2 | $31.2M | Buy |
377,878
+12,593
| +3% | +$1.05M | 0.5% | 61 |
|
|
2023
Q1 | $29.5M | Buy |
365,285
+289,169
| +380% | +$24M | 0.51% | 61 |
|
|
2022
Q4 | $6.29M | Hold |
76,116
| – | – | 0.11% | 137 |
|
|
2022
Q3 | $6M | Hold |
76,116
| – | – | 0.11% | 134 |
|
|
2022
Q2 | $5.65M | Sell |
76,116
-30,873
| -29% | -$2.32M | 0.1% | 134 |
|
|
2022
Q1 | $9.62M | Sell |
106,989
-3,695
| -3% | -$341K | 0.14% | 118 |
|
|
2021
Q4 | $12.4M | Sell |
110,684
-116,045
| -51% | -$14M | 0.2% | 100 |
|
|
2021
Q3 | $28.5M | Buy |
226,729
+144,890
| +177% | +$18.7M | 0.47% | 65 |
|
|
2021
Q2 | $11.1M | Buy |
81,839
+29,273
| +56% | +$3.85M | 0.28% | 83 |
|
|
2021
Q1 | $7.13M | Buy |
+52,566
| New | +$7.87M | 0.2% | 106 |
|
|
2020
Q4 | – | Sell |
-41,437
| Closed | -$4.62M | – | 472 |
|
|
2020
Q3 | $4.62M | Buy |
41,437
+25,615
| +162% | +$2.87M | 0.23% | 81 |
|
|
2020
Q2 | $1.77M | Sell |
15,822
-212,745
| -93% | -$21M | 0.11% | 103 |
|
|
2020
Q1 | $17.7M | Buy |
228,567
+225,332
| +6,965% | +$20M | 1.32% | 25 |
|
|
2019
Q4 | $308K | Sell |
3,235
-17,113
| -84% | -$1.48M | 0.02% | 319 |
|
|
2019
Q3 | $1.56M | Buy |
+20,348
| New | +$1.69M | 0.11% | 109 |
|
|
2019
Q2 | – | Sell |
-20,348
| Closed | -$1.84M | – | 489 |
|
|
2019
Q1 | $1.84M | Buy |
+20,348
| New | +$1.73M | 0.1% | 120 |
|
|
2018
Q4 | – | Sell |
-31,422
| Closed | -$3.01M | – | 453 |
|
|
2018
Q3 | $3.01M | Buy |
31,422
+300
| +1% | +$29.1K | 0.15% | 90 |
|
|
2018
Q2 | $10.8M | Buy |
+31,122
| New | +$2.86M | 0.48% | 59 |
|
Other funds holding XBI
Meitav Investment House's XBI Position: Q2 2026 in Review
Meitav Investment House reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.9% in Q2 2026, selling an estimated $2.03M and leaving 794,579 shares worth $126M. The position accounts for 0.85% of the portfolio, ranked #31.
Meitav Investment House first reported a position in XBI in Q2 2018 and has held it in 30 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Meitav Investment House held 794,579 shares of State Street SPDR S&P Biotech ETF worth $126M as of Q2 2026.
- Meitav Investment House sold 15,000 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $2.03M.
- State Street SPDR S&P Biotech ETF made up 0.85% of Meitav Investment House's portfolio in Q2 2026, its #31 holding.
- Meitav Investment House first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 30 quarters since.
- 936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Meitav Investment House's 13F filing for Q2 2026, filed 20 Jul 2026.